Efficacy of Mepolizumab for Long-term Treatment in Patients with Severe Asthma

Mepolizumab is a monoclonal antibody against interleukin-5 used for the treatment of severe asthma. The effect of long-term mepolizumab administration and its persistence in clinical practice is poorly understood. Thus, this study aimed to investigate the effect of long-term administration of mepoli...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:The Showa University Journal of Medical Sciences 2020, Vol.32(4), pp.247-256
Hauptverfasser: MIYATA, Yoshito, OHTA, Shin, TANAKA, Akihiko, AKIMOTO, Kaho, SATO, Hiroki, UNO, Tomoki, SATO, Haruna, UCHIDA, Yoshitaka, JINNO, Megumi, HIRAI, Kuniaki, INOUE, Hideki, HONMA, Tetsuya, YAMAMOTO, Mayumi, SUZUKI, Shintaro, SAGARA, Hironori
Format: Artikel
Sprache:eng
Schlagworte:
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
Beschreibung
Zusammenfassung:Mepolizumab is a monoclonal antibody against interleukin-5 used for the treatment of severe asthma. The effect of long-term mepolizumab administration and its persistence in clinical practice is poorly understood. Thus, this study aimed to investigate the effect of long-term administration of mepolizumab in patients with severe asthma. Mepolizumab was administered to 20 patients with severe asthma. We then prospectively followed the patients for 104 weeks to investigate the efficacy of long-term mepolizumab administration in clinical practice. Eleven patients were evaluated for 104 weeks. Mepolizumab administration reduced asthma exacerbations in a year from 52 to 104 weeks and improved asthma control in every period as assessed by questionnaires. Also, blood eosinophil counts decreased at every point, and blood basophil counts decreased at 104 weeks. We compared various parameters among the 11 patients who continued administration for more than 104 weeks and 7 patients who discontinued treatment due to ineffectiveness. Significant differences were observed in disease duration, maximum expiratory flow at 50%, and blood basophil count. Long-term mepolizumab administration improved asthma symptoms in patients with severe asthma and reduced the frequency of exacerbations.
ISSN:0915-6380
2185-0968
DOI:10.15369/sujms.32.247